VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.
Department of Oncology, KU Leuven, Leuven, Belgium.
Cancer Res. 2021 Aug 15;81(16):4218-4229. doi: 10.1158/0008-5472.CAN-20-3669. Epub 2021 Jul 2.
Meningiomas are the most common benign brain tumors. Mutations of the E3 ubiquitin ligase TRAF7 occur in 25% of meningiomas and commonly cooccur with mutations in KLF4, yet the functional link between TRAF7 and KLF4 mutations remains unclear. By generating an meningioma model derived from primary meningeal cells, we elucidated the cooperative interactions that promote meningioma development. By integrating TRAF7-driven ubiquitinome and proteome alterations in meningeal cells and the TRAF7 interactome, we identified TRAF7 as a proteostatic regulator of RAS-related small GTPases. Meningioma-associated TRAF7 mutations disrupted either its catalytic activity or its interaction with RAS GTPases. TRAF7 loss in meningeal cells altered actin dynamics and promoted anchorage-independent growth by inducing CDC42 and RAS signaling. TRAF deficiency-driven activation of the RAS/MAPK pathway promoted KLF4-dependent transcription that led to upregulation of the tumor-suppressive Semaphorin pathway, a negative regulator of small GTPases. KLF4 loss of function disrupted this negative feedback loop and enhanced mutant TRAF7-mediated cell transformation. Overall, this study provides new mechanistic insights into meningioma development, which could lead to novel treatment strategies. SIGNIFICANCE: The intricate molecular cross-talk between the ubiquitin ligase TRAF7 and the transcription factor KLF4 provides a first step toward the identification of new therapies for patients with meningioma.
脑膜瘤是最常见的良性脑肿瘤。E3 泛素连接酶 TRAF7 的突变发生在 25%的脑膜瘤中,通常与 KLF4 的突变共同发生,然而 TRAF7 和 KLF4 突变之间的功能联系仍不清楚。通过生成源自脑膜细胞的脑膜瘤模型,我们阐明了促进脑膜瘤发展的协同相互作用。通过整合脑膜细胞中 TRAF7 驱动的泛素组和蛋白质组改变以及 TRAF7 相互作用组,我们确定 TRAF7 是 RAS 相关小 GTPase 的蛋白稳态调节剂。脑膜瘤相关的 TRAF7 突变破坏了其催化活性或与 RAS GTPase 的相互作用。脑膜细胞中 TRAF7 的缺失改变了肌动蛋白动力学,并通过诱导 CDC42 和 RAS 信号促进锚定非依赖性生长。TRAF 缺陷驱动的 RAS/MAPK 途径的激活促进了 KLF4 依赖性转录,导致肿瘤抑制性 Semaforin 途径的上调,这是小 GTPase 的负调节剂。KLF4 功能丧失破坏了这个负反馈环,并增强了突变 TRAF7 介导的细胞转化。总的来说,这项研究为脑膜瘤的发展提供了新的机制见解,这可能为脑膜瘤患者带来新的治疗策略。
泛素连接酶 TRAF7 和转录因子 KLF4 之间复杂的分子相互作用为鉴定新的脑膜瘤治疗方法提供了第一步。